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Pancreatic cancer is molecularly diverse, with few effective therapies. Increased 
mutation burden and defective DNA repair are associated with response to immune 
checkpoint inhibitors in several other cancer types. We interrogated 385 pancreatic 
cancer genomes to define hypermutation and its causes. Mutational signatures 
inferring defects in DNA repair were enriched in those with the highest mutation 
burdens. Mismatch repair deficiency was identified in 1% of tumors harbouring 
different mechanisms of somatic inactivation of MLH1 and MSH2. Defining mutation 
load in individual pancreatic cancers and the optimal assay for patient selection 
may inform clinical trial design for immunotherapy in pancreatic cancer.  
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Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival of less than 5% with 
therapies offering only incremental benefit1, potentially due to the diversity of its genomic 
landscape2-4. Recent reports link high mutation burden with response to immune 
checkpoint inhibitors in several cancer types5, Defining tumors that are hypermutated with 
an increased mutation burden and understanding the underlying mechanisms in 
pancreatic cancer has the potential to advance therapeutic development, particularly for 
immunotherapeutic strategies.  
Whole genome (WGS, n=180) and whole exome (n=205) sequencing of 385 unselected 
predominantly sporadic PDAC (Supplementary Table 1) defined an average mutation load 
of 1.8 and 1.1 mutation per megabase (Mb) respectively (Supplementary Table 2). Outlier 
analysis identified 20 samples with the highest mutation burden (5.2%, 15 WGS and 5 
exome) (Table 1 and Supplementary Figure 1A), 5 of which were considered extreme 
outliers and classified as hypermutated as they contained ≥12 somatic mutations/Mb, the 
defined threshold for hypermutation in colorectal cancer 6. Immunohistochemistry (IHC) for 
mismatch repair (MMR) proteins (MSH2, MSH6, MLH1 and PMS2) identified 4 MMR 
deficient tumors, all of which were hypermutated (n = 180, Figure 1).  
KRAS mutation status and histopathological characteristics have been associated with 
MMR deficient pancreatic tumors7. Of the 4 MMR deficient tumors in our cohort, 2 were 
KRAS wild type; 3 had undifferentiated to moderately differentiated histology and one a 
signet-ring component. These features were not predictive of MMR deficiency in our cohort 
as 11 additional non-MMR deficient tumors had a signet-ring cell component or colloid 
histology and 131 of 347 assessable tumors had poorly- or un-differentiated histology.  
Mutational signature analysis can detect MMR deficiency indirectly based on somatic 
mutations8. An MMR deficient signature dominated the MMR deficient tumors (with WGS), 
and was minimal in MMR intact tumors (Supplementary Figure 1). In addition, 
microsatellite instability (MSI), a hallmark of MMR deficiency in colorectal cancer, was 
detected in all three MMR deficient tumors with WGS using MSIsensor9 (Supplementary 
Table 2). MSI was not identified for the fourth MMR deficient sample potentially due to the 
reduced number of microsatellite loci in exome data.  
The underlying causes of MMR deficiency in the 4 cases were private somatic events. For 
2 cases MSH2 was disrupted by different structural rearrangements, 1 case contained a 
missense MSH2 mutation and the last, methylation of the MLH1 promoter (Figure 1). The 
missense mutation caused an MSH2 splice acceptor site mutation that alters the same 
nucleotide reported to result in a pathogenic skipping of exon 13 in germline studies10. 
Hypermethylation of the MLH1 promoter is the predominant mechanism of MSI in sporadic 
colon cancer11. The remaining hypermutated tumor contained an intact MMR pathway, 
and was a cell line (ATCC, CRL-2551) with an unidentified mutational signature; therefore 
the high mutation burden in this sample may be the result of long term cell culture. 
The 15 samples (11 WGS and 4 exome) identified in the outlier analysis with high mutation 
burden, but not hypermutated (~4 - 12 mutations/Mb) contained no evidence of MMR 
deficiency. Mutational signature analysis of the WGS samples indicated homologous 
recombination (HR) repair deficiency as the most substantial (range 1.0 - 3.4 
mutations/Mb) contributor to the mutation burden for 8 WGS mutation load outlier tumors. 
In support of a HR defect4; 7 of these tumors contained high levels of genomic instability 
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with >200 structural variants and mutations in genes involved in HR were present for 6/8 
cases (Supplementary Table 2). In addition, one case that had undergone exome 
sequencing had a somatic BRCA2 nonsense mutation that likely contributed to HR 
deficiency in this sample. A mutational signature associated with T>G mutations at TT 
sites previously described in other cancers, including esophageal cancer12 was the major 
contributor (>3 mutations/Mb) in 2 samples. For these two and the remaining 4 cases, no 
potential causative event could be identified. 
Although germline defects in MMR genes are well reported in pancreatic cancer13 in our 
cohort, they did not contribute to MMR deficiency even in those with familial pancreatic 
cancer or a personal or family history of Lynch-related tumors. A germline truncating 
variant was detected in PMS2 for 1 case but did not have loss of the second allele, 
therefore had normal IHC staining and did not display a MMR mutational signature 
(Supplementary Table 2). MMR deficiency is important in the evolution in a small, but 
meaningful proportion of pancreatic cancers with a prevalence of 1% (4/385) in our cohort. 
This is consistent with recent studies using the Bethesda PCR panel14, and with previous 
estimates of MSI prevalence of 2-3%15. However, in tumors with low epithelial content that 
underwent exome sequencing, the sensitivity of somatic mutation detection is reduced, 
which will affect mutation burden and signature analysis. Whilst cognizant of small 
numbers, immunohistochemistry was the most accurate in defining MMR due to multiple 
genomic mechanisms of MMR gene inactivation. Multiple methods to define MMR 
deficiency may be required for clinical trials that aim to recruit MMR deficient participants 
for clinical trials examining checkpoint inhibitors or other therapies in pancreatic cancer. 
Homologous recombination deficient tumors, and those with a novel signature seen in 
esophageal cancer had an increased mutation burden, and need further evaluation as 
potential patient selection markers for clinical trials of checkpoint inhibitor and other 
therapies that target tumors with a high mutation burden. 
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Figure Legends 
Figure 1. Molecular mechanisms of MMR deficiency. IHC images (scale bars indicate 
100µm) indicating loss of staining of MMR proteins in tumor cells (blue) and normal 
staining in adjacent cells (brown) with schematics of underlying genetic aetiology. A, 
MHS2 absence due to a homozygous deletion (ICGC_0076). B, MHS2 absence and a 
structural rearrangement disrupting the MSH2 locus through insertion of a 27Kb DNA 
segment (ICGC_0548). C, MHS2 absence and a missense acceptor splice site variant at 
exon 13 (ICGC_0090). D, MLH1 absence through hypermethylation of the promoter region 
(ICGC_0297). The average beta value of 45 CpG sites in the promoter of MLH1 for 
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Table 1. Clinical and histological features and proposed aetiology for highly mutated PDAC tumors (n=20). 
Sample ID Personal and  family 
history of malignancy  
Histology Mutation Load 
(Mutations/Mb) 







SV subtype (no 
of events) 
 
 Proposed aetiology 
Hypermutation (extreme outliers) 
ICGC_0076† None Mixed signet ring, mucinous 
and papillary adenocarcinoma. 
38.55 Absent MLH1 
and PMS2 
28.3 p.G12V MMR (18.3) Scattered (131) MMR deficiency: >280kb somatic 
homozygous deletion over MSH2 
ICGC_0297† None Undifferentiated 
adenocarcinoma 
60.62 Absent MSH2 
and MSH6 
27.33 WT MMR (33.4) Scattered (75) MMR deficiency: Somatic MLH1 promoter 
hypermethylation 
ICGC_0548† None Ductal adenocarcinoma, 
moderately differentiated 
30.13 Absent MSH2 
and MSH6 
17.47 WT MMR (16.6) Stable (49) MMR deficiency: >27kb somatic inversion 
rearrangement disrupting MSH2 
ICGC_0328† None Ductal adenocarcinoma 16.63 Normal. 3.2 p.G12D Unknown (11.9) Scattered (110) Cell line with signature: etiology unknown. 
ICGC_0090 1 FDR, father CRC Ductal adenocarcinoma, 
moderately differentiated 
12.9 Absent MSH2 
and MSH6 
0.21 p.G12C N/A N/A MMR deficiency: Somatic MSH2 splice site 
c.2006G>A 
Highly mutated tumors 
ICGC_0054† None Ductal adenocarcinoma, poorly 
differentiated 
6.52 Normal 0.01 p.G12V HR deficiency (1.3) Unstable (310) HR deficiency: No germline or somatic cause 
found. 
ICGC_0290† None Ductal adenocarcinoma, poorly 
differentiated 
6.54 Not Available 0.07 p.G12V HR deficiency (3.1) Unstable (558) HR deficiency: Germline BRCA2 mutation 
c.7180A>T, p.A2394*. Somatic CN-LOH.  
ICGC_0215† 2 FDR lung cancer, 2 
FDR prostate cancer. 




6.27 Normal 0.01 p.G12V HR deficiency (1.9) Scattered (111) HR deficiency: Germline ATM mutation 
c.7539_7540delAT, p.Y2514*. Somatic CN-
LOH. 
ICGC_0324 None Ductal adenocarcinoma, 
moderately differentiated 
6.24 Normal 0  p.G12D N/A N/A Undefined 
ICGC_0034† None Ductal adenocarcinoma, poorly 
differentiated 
6.09 Normal 4.02 p.G12D HR deficiency (3.4) Unstable (366) HR deficiency: Germline BRCA2 mutation 
c.5237_5238insT, p.N1747*. Somatic CN-
LOH. 
ICGC_0131† lung cancer after PC Ductal adenocarcinoma, 
moderately differentiated 
5.63 Normal 0 p.G12D T>G at TT sites (3.0) Focal (147) T>G at TT sites signature: etiology potentially 
associated with DNA oxidation 
ICGC_0006† 1 FDR, father lung cancer Adenocarcinoma arising from 
IPMN, moderately differentiated 
5.29 Normal 0.01 p.G12D HR deficiency (1.2) Unstable (211) HR deficiency: Somatic BRCA2 c.5351dupA, 
p.N1784KfsTer3. Somatic CN-LOH. 
ICGC_0321† 2 FDR, mother and 
cousin breast cancer 
Ductal adenocarcinoma, poorly 
differentiated 
4.79 Not Available 0 p.G12D HR deficiency (2.1) Unstable (286) HR deficiency: Germline BRCA2 c.6699delT, 
p.F2234LfsTer7. Somatic CN loss- 1 copy. 
ICGC_0309† None Adenocarcinoma arising from 
IPMN, moderately differentiated 
4.74 Normal 0.03 p.G12V T>G at TT sites (3.1) Unstable (232) T>G at TT sites signature: etiology potentially 
associated with DNA oxidation 
ICGC_0005† 1 FDR, mother CRC Ductal adenocarcinoma, poorly 
differentiated 
4.72 Not Available 1 p.G12V HR deficiency (1.1) Focal (95) HR deficiency: No germline or somatic cause 
found. 
ICGC_0016† None Ductal adenocarcinoma, poorly 
differentiated 
4.61 Normal 3.03 p.G12V HR deficiency (1.7) Unstable (447) HR deficiency: potentially linked to Somatic 
RPA1 c.273G>T, p.R91S 
ICGC_0046 1 FDR, brother PC Ductal adenocarcinoma, poorly 
differentiated 
4.3 Normal 0 p.Q61H N/A N/A Undefined 
GARV_0668† None Ductal adenocarcinoma, poorly 
differentiated 
4.3 Not Available 2.19 p.G12V HR deficiency (1.6) Unstable (464) HR deficiency: Germline BRCA2 
c.7068_7069delTC, p.L2357VfsTer2. Somatic 
CN loss - 1 copy. 
ICGC_0291 None Ductal adenocarcinoma, well 
differentiated 
3.84 Not Available 0.03 p.G12R N/A N/A HR deficiency: Somatic BRCA2 c.7283T>A, 
p.L2428* 
ICGC_0256 None Ductal adenocarcinoma, poorly 
differentiated 
3.72 Not Available 0.06 p.G12D N/A N/A Undefined 
† Sample sequenced by whole genome sequencing (WGS), other samples by exome sequencing  
FDR, First degree relative; PC, Pancreatic cancer; CRC, Colorectal cancer; N/A, not applicable to exome data. 
